Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donna Mildvan

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2004
"Informed altruism" and "partner restriction" in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001Don C Des Jarlais, Theresa Perlis, Kamyar Arasteh, et al.
Current HIV/AIDS Reports|August 26, 2010
Increasing and supporting the participation of persons of color living with HIV/AIDS in AIDS clinical trialsMarya Viorst Gwadz, Pablo Colon, Amanda S Ritchie, et al.
AIDS Patient Care and Stds|August 23, 2007
Attitudes and perceptions of AIDS clinical trials group site coordinators on HIV clinical trial recruitment and retention: a descriptive studyWilliam D King, Donna Defreitas, Kimberly Smith, et al.
AIDS (London, England)|October 28, 2005
Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001Don C Des Jarlais, Theresa Perlis, Kamyar Arasteh, et al.
Archives of Internal Medicine|July 15, 2009
Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trialRobert Gross, Camlin Tierney, Adriana Andrade, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 29, 2012
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot studyAnthony Mills, Donna Mildvan, Daniel Podzamczer, et al.
AIDS and Behavior|April 4, 2015
Behavioral intervention improves treatment outcomes among HIV-infected individuals who have delayed, declined, or discontinued antiretroviral therapy: a randomized controlled trial of a novel interventionMarya Gwadz, Charles M Cleland, Elizabeth Applegate, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 3, 2010
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trialCharles Flexner, Camlin Tierney, Robert Gross, et al.
Antimicrobial Agents and Chemotherapy|August 28, 2013
Nested case-control study of the emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniaeMasayuki Nigo, Catalina Salinas Cevallos, Krystina Woods, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2004
Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248)Mary A Vogler, Hedy Teppler, Rebecca Gelman, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2004
"Informed altruism" and "partner restriction" in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001Don C Des Jarlais, Theresa Perlis, Kamyar Arasteh, et al.
Current HIV/AIDS Reports|August 26, 2010
Increasing and supporting the participation of persons of color living with HIV/AIDS in AIDS clinical trialsMarya Viorst Gwadz, Pablo Colon, Amanda S Ritchie, et al.
AIDS Patient Care and Stds|August 23, 2007
Attitudes and perceptions of AIDS clinical trials group site coordinators on HIV clinical trial recruitment and retention: a descriptive studyWilliam D King, Donna Defreitas, Kimberly Smith, et al.
AIDS (London, England)|October 28, 2005
Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001Don C Des Jarlais, Theresa Perlis, Kamyar Arasteh, et al.
Archives of Internal Medicine|July 15, 2009
Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trialRobert Gross, Camlin Tierney, Adriana Andrade, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 29, 2012
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot studyAnthony Mills, Donna Mildvan, Daniel Podzamczer, et al.
AIDS and Behavior|April 4, 2015
Behavioral intervention improves treatment outcomes among HIV-infected individuals who have delayed, declined, or discontinued antiretroviral therapy: a randomized controlled trial of a novel interventionMarya Gwadz, Charles M Cleland, Elizabeth Applegate, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 3, 2010
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trialCharles Flexner, Camlin Tierney, Robert Gross, et al.
Antimicrobial Agents and Chemotherapy|August 28, 2013
Nested case-control study of the emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniaeMasayuki Nigo, Catalina Salinas Cevallos, Krystina Woods, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2004
Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248)Mary A Vogler, Hedy Teppler, Rebecca Gelman, et al.
Pageof 5